DSM Firmenich (DSFIR) Q3 2024 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 TU earnings summary
8 Jul, 2026Executive summary
Achieved strong organic growth and financial improvement in Q3 2024, with all business units contributing and synergy and transformation programs progressing well.
Animal Nutrition & Health (ANH) separation is well advanced, alongside strategic portfolio adjustments including the sale of marine lipids and yeast extracts.
Sustainability milestone reached with net-zero emissions targets validated by the Science Based Targets initiative, and a dedicated sustainability event planned for early 2025.
Upgraded full-year 2024 EBITDA outlook to approximately €2.1 billion, reflecting positive business momentum and a temporary profit boost from higher vitamin prices due to supply disruption.
Financial highlights
Q3 2024 sales rose 8% year-over-year to €3,244 million, with organic sales growth of 8% and group volume growth of 9%.
Adjusted EBITDA for Q3 2024 was €541 million, up 32% year-over-year, with margin improving to 16.7% (up 330bps).
Year-to-date Q3 2024 sales reached €9,542 million, up 4% year-over-year, and adjusted EBITDA was €1,517 million, up 13%.
Adjusted gross operating free cash flow for the first nine months was €879 million, reflecting disciplined working capital management.
Perfumery & Beauty delivered 11% volume growth and a 22.8% EBITDA margin; Taste, Texture & Health volumes up 13%, EBITDA up 21% to €162 million, margin 19.7%.
Outlook and guidance
Full-year 2024 adjusted EBITDA outlook raised to €2.1 billion, including a temporary profit boost of about €80 million in Q4 from higher vitamin prices.
CapEx expected at €0.8 billion for FY 2024, with D&A around €235 million per quarter and core income tax rate near 24%.
Expect continued strong business conditions into Q4, with regular seasonality in Perfumery & Beauty and Taste, Texture & Health, and a negative FX impact similar to Q3.
Anticipate Q1 2024 to benefit from vitamin price tailwinds, with €100 million expected in ANH and some improvement in Health, Nutrition & Care.
Latest events from DSM Firmenich
- 7% organic sales growth and 29% EBITDA rise in H1 2025, with strong outlook and portfolio actions.DSFIR
H1 20259 Jul 2026 - 2026–2028 targets: 2%-4% sales growth, 20%-23% EBITDA margin, and €540M share buyback.DSFIR
Investor update9 Jul 2026 - Q1 saw 4% LFL sales growth, margin resilience, and strategic capital actions including a dual listing.DSFIR
Q1 2026 TU6 May 2026 - H1 2024 saw higher sales, EBITDA, and guidance, with strong P&B and TTH growth.DSFIR
H1 202410 Mar 2026 - 3% organic sales growth and resilient margins achieved despite ANH divestment and macro headwinds.DSFIR
Q4 202512 Feb 2026 - Divesting Animal Nutrition & Health for EUR 2.2bn, launching EUR 0.5bn buyback, and refocusing on core.DSFIR
Status update9 Feb 2026 - Accelerated shift to high-growth nutrition, health, and beauty targets 5–7% growth, 22–23% EBITDA.DSFIR
CMD 202431 Jan 2026 - Separation of Animal Nutrition & Health set for 2025, targeting EUR 10B sales and >22% margins.DSFIR
Deutsche Bank’s Depositary Receipts Virtual Investor Conference20 Jan 2026 - 2024 saw robust growth, margin expansion, and €2bn divestments, with a strong 2025 outlook.DSFIR
Q4 20248 Jan 2026